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Accuracy of Plasma B-Type Natriuretic Peptide to
Diagnose Significant Cardiovascular Disease in Children
The Better Not Pout Children! Study
Yuk M. Law, MD,* Andrew W. Hoyer, MD,† Mark D. Reller, MD,‡ Michael Silberbach, MD‡
Seattle, Washington; Charlottesville, Virginia; and Portland, Oregon
Objectives The purpose of this study was to assess the ability of plasma B-type natriuretic peptide (BNP) to diagnose signifi-
cant cardiovascular disease (CVD) in the pediatric population.
Background BNP has been shown to be reliable in detecting ventricular dysfunction and heart failure in adults. Timely and
accurate identification of significant pediatric heart disease is important but challenging. A simple blood test
could aid the front-line physician in this task.
Methods Subjects without a history of heart disease with findings possibly attributable to significant CVD in the acute care
setting requiring a cardiology consult were enrolled. Clinicians were blinded to the BNP result, and confirmation
of disease was made by cardiology consultation.
Results Subjects were divided into a neonatal (n  42, 0 to 7 days) and older age group (n  58, 7 days to 19 years).
CVD was present in 74% of neonates and 53% of the older age group. In neonates with disease, median BNP
was 526 pg/ml versus 96 pg/ml (p  0.001) for those without disease. In older children with disease, median
BNP was 122 pg/ml versus 22 pg/ml in those without disease (p  0.001). Subjects with disease from an ana-
tomic defect, a longer hospital stay, or who died had higher BNP. A BNP of 170 pg/ml yielded a sensitivity of
94% and specificity of 73% in the neonatal group and 87% and 70% in the older age group, respectively, using a
BNP of 41 pg/ml.
Conclusions BNP is a reliable test to diagnose significant structural or functional CVD in children. Optimal cutoff values are
different from adult values. (J Am Coll Cardiol 2009;54:1467–75) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.020o
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sardiovascular disease (CVD) of childhood is important to
ecognize at its presentation, but this is often a challenging
ask. The spectrum of diseases is heterogeneous, and no
ingle entity predominates. To complicate matters, the
hysiology of the cardiovascular system in children is not
tatic and changes with growth and development. Further-
ore, children are poor historians, and with the high
revalence of respiratory infections in the pediatric popula-
ion, significant underlying cardiac disease can be obscured.
n acute care settings, pediatric cardiologists may not always
e available to assist front-line providers in the proper triage
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egional Medical Center, University of Washington, Seattle, Washington; †Univer-
ity of Virginia, Charlottesville, Virginia; and the ‡Doernbecher Children’s Hospital,
regon Health & Science University, Portland, Oregon. This study was supported by
grant from the Friends of Doernbecher Foundation, Oregon Health & Science
niversity, Portland, Oregon. The Triage BNP assay and reagents were an unre-
tricted gift for the purpose of research and education from Biosite Inc., San Diego,
alifornia. It was a 1-time transaction, and Biosite was never involved in the design
or has any knowledge of the results of the study.v
Manuscript received December 16, 2008; revised manuscript received May 13,
009, accepted June 2, 2009.f the compromised patient. Traditional diagnostic studies
uch as chest radiography (CXR) and electrocardiography
re also not accurate in identifying cardiovascular abnormal-
ties (1,2). Consequently, patients with significant CVD are
ometimes diagnosed with delay or are transported long
istances unnecessarily.
See page 1476
Although a simple screening test (pulse oximetry) exists
or cyanotic heart disease, the same cannot be said for
emodynamically significant cardiac lesions. Plasma B-type
atriuretic peptide (BNP) is a hormone secreted by the atria
nd ventricles (3) and is part of an intricate homeostatic
etwork that regulates the circulating blood volume. It is
levated under conditions of increased wall stress (4,5), such
s with increased preload or afterload and decreased systolic
r diastolic ventricular function. Large prospective studies
erformed in the acute care setting in adults have demon-
trated the value of circulating BNP as a method to diagnose
entricular dysfunction and heart failure (6–10). The mea-
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BNP to Diagnose Significant CVD October 6, 2009:1467–75surement of BNP is available as a
rapid automated point-of-care
antibody fluorescent test, requir-
ing 0.5 ml of whole blood,
which can be obtained from fin-
ger stick. BNP values in the
healthy population are age-
related, and although BNP val-
ues for healthy children have
been published (11–14) and
small studies have shown BNP to
be elevated in various types of con-
genital cardiac defects (15–17),
either the accuracy nor the utility of BNP in diagnosing
emodynamically significant heart disease in children has
een rigorously examined. The Better Not Pout Children!
tudy was a field test to evaluate the accuracy of BNP as a
apid triage tool to diagnose significant CVD in the pedi-
tric population. The hypothesis is that a single plasma
NP measurement can be used to accurately identify
ignificant CVD in infants and children using the cardiol-
gy consultant’s evaluation as the gold standard.
ethods
ubjects and diagnosis of significant CVD. This was a
rospective study from a single pediatric center with blind-
ng of the diagnosticians to the BNP test results. Subjects
ere between 36 weeks’ gestational age (corrected) to 19
ears of age and had no known cardiovascular abnormality.
ubjects were eligible for enrollment upon request by a
oncardiologist for an urgent pediatric cardiology consult to
valuate a patient presenting with signs or symptoms that
ay be attributable to a significant cardiovascular abnor-
ality, such as dyspnea, failure to thrive, swelling, hypoten-
ion, and so on. Similarly, subjects with an isolated murmur
r spontaneously resolved palpitations who were otherwise
symptomatic were not eligible. Other exclusion criteria
ncluded sepsis, renal dysfunction requiring therapy, insuf-
cient data for the cardiologist to form a diagnosis, or
ardiovascular-specific treatment, for example, diuretics,
asodilators, inotropes, vasoconstrictors, and the like, hav-
ng been started more than 6 h before sample collection.
Because the spectrum of significant CVD in children is
road, the common defining feature of “significant” was
hether the function or the structure of the heart had been
ltered by the cardiovascular abnormality as officially inter-
reted by the consulting cardiologist. Abnormal function
ncluded systolic dysfunction with shortening fraction
28% or a qualitative decrease and diastolic dysfunction,
hich was defined as indirect signs of elevated filling
ressures, such as enlarged atria, or the presence of heart
ailure in the absence of systolic dysfunction. Altered struc-
ure included an abnormality in the chamber size (e.g., from
ncreased pre-load) or myocardial thickness (e.g., from
Abbreviations
and Acronyms
BNP  B-type natriuretic
peptide
CVD  cardiovascular
disease
CXR  chest X-ray
NPV  negative predictive
value
PPV  positive predictive
valuencreased afterload) attributable to a cardiac defect (e.g., ientricular septal defect) or a cardiovascular abnormality
ithout an anatomic defect (e.g., pulmonary hypertension
r systemic hypertension). Because pulmonary arterial hy-
ertension is a common manifestation of hemodynamically
ignificant CVD, it was defined by echocardiography di-
ectly as a right ventricular or pulmonary systolic pressure
hat is over one-half systemic or indirectly by flattening of
he interventricular septum or right-to-left shunting at the
entricular or aortic level during any part of the cardiac
ycle. Lastly, CVD is further divided into those with an
natomic defect and those without. An anatomic defect is
efined as an inherent structural abnormality in the circu-
ation that is either congenital or acquired, such as coarcta-
ion of the aorta or rheumatic valve disease.
A cardiac finding was classified as insignificant if it was
hought to be unrelated to the symptoms that prompted the
nitial request for consultation. For example, a subject with
bicuspid aortic valve and a 2-m/s gradient without
lteration in structure or function, and the illness not
onsistent with the cardiovascular abnormality found, would
ot be placed in the group of significant CVD.
The consulting cardiologist determined the diagnostic
ests required (echocardiogram was not required), made the
fficial diagnosis, and filed a study form to define whether
n alteration of function or structure was present. The study
opulation was divided into the neonatal group (7 days of
ge) and the older age group (the rest of the subjects up to
9 years of age). Consent and/or assent were obtained from
ll subjects and their legal guardians. The study was ap-
roved by the local institutional review board.
NP assay. Blood samples collected from indwelling vas-
ular catheters, venipuncture, or finger/heel stick were
ransported immediately in potassium (K2) ethylenedi-
minetetra acetic acid tubes and assayed within 4 h. Samples
ere collected within 24 h of the consult. Subjects were
nrolled from any acute care facility of the medical center
e.g., emergency department, inpatient wards, nursery, and
ntensive care units). Plasma BNP was measured using the
riage BNP point-of-care assay (Biosite Inc., San Diego,
alifornia). This assay has a linear dynamic range from 5
o 5,000 pg/ml, with an intraday precision standard devia-
ion of 8.8% to 11.6% over this range. Maintenance and
uality performance assurance of the instrument were
trictly followed according to company instructions.
tatistical analysis. Descriptive data are presented as me-
ian with range and mean SD. Comparison of the groups
as done by nonparametric methods using the Mann-
hitney U test between 2 groups and the Kruskal-Wallis H
est among more than 2 groups. The distribution of BNP
alues is illustrated by box-and-whisker plots (Tukey),
here the heavy solid line indicates the median, the box
epresents the interquartile range (25% to 75%), and
hiskers are drawn to 1.5 times the interquartile range.
ivariate analysis for length of stay was performed using
he method of Spearman. Receiver-operating character-
stic curves, accuracy calculations, figures, and all statis-
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October 6, 2009:1467–75 BNP to Diagnose Significant CVDical analyses were generated using SPSS version 15.0
SPSS Inc., Chicago, Illinois). Statistical significance was
ccepted for p  0.05.
esults
ubject characteristics. The study was conducted over a
0-month period, with 102 subjects enrolled and 100
ulfilling the final study criteria. Table 1 describes the
emographic characteristics of the study population. All
ubjects had clinical features that posed the possibility of
ignificant CVD to the referring physician. The majority of
he subjects were neonates and infants, as shown by the age
nd weight distribution. In addition, 28% of subjects were
rom the inpatient ward, 15% from the pediatric intensive
are unit, 46% from the neonatal intensive care unit/nursery,
nd 11% from the emergency department. This distribution
y location of subjects also reflected the large number of
oung infants in the study. An echocardiogram was per-
ormed in 97% of the subjects. All subjects with CVD had
n echocardiogram. CXR was performed in 92% of the
ubjects, 93% in the disease group, and 90% in the nondis-
ase group. There was no statistical difference between the
isease and nondisease groups (total and age groups) in regard
o having had an echocardiogram or CXR. Abnormalities on
XR included enlarged heart size (30%), increased/decreased
ascularity (9%), edema (8%), or parenchymal disease
50%). Patients with an abnormal CXR had a median BNP
f 263 pg/ml (range 5 to 5,000 pg/ml); patients with a
ormal CXR had a median BNP of 47 pg/ml (range 5 to
,890 pg/ml, p  0.009).
To be enrolled in the study, subjects were required to
resent with signs and/or symptoms that led the front-line
hysician to suspect significant CVD. All subjects had
ymptoms possibly referable to the cardiovascular system,
ith the most common being dyspnea (neonatal 64%, older
ge 60%), hypoxemia (neonatal 45%, older age 19%),
emographics of the Study PopulationTable 1 Demographics of the Study Population
Combined
Total group
n (%) 100
Female (%) 39 (39)
Median age at consult, months (range) 0.52 (0–225)
Median weight, kg (range) 3.8 (1.8–99)
Neonatal group
n (%) 42
Female (%) 16 (38)
Median age at consult, days (range) 1 (0–5)
Median weight, kg (range) 3.2 (2.1–4.8)
Older age group
n (%) 58
Female (%) 23 (40)
Median age at consult, months (range) 2.5 (0.27–225)
Median weight, kg (range) 4.7 (1.8–99)Statistical comparison between the disease and nondisease group.eeding/gastrointestinal/growth difficulties (neonatal 5%,
lder age 17%), fatigue or lethargy (neonatal 10%, older age
4%), and collapse (neonatal 0%, older age 7%). There was
correlation between the symptoms recognized by the
ront-line physician and consulting cardiologist. The most
ommon abnormal physical examination findings referable
o the cardiovascular system included an abnormal pre-
ordial impulse, S3/S4, loud single S2, edema, jugular venous
istension, hepatomegaly, decreased perfusion or pulses,
nd breath sounds (Table 2). There was a weak correlation
n physical findings as reported between the front-line
hysician and cardiologist. The prevalence of 1 or more
bnormal physical findings, as detected by the cardiology
onsultant, was 76% in those with significant CVD, whereas
hese findings were present in 33% of those without disease.
n the older age group with disease, 67% had 1 or more
bnormal physical findings; 36% had 1 or more abnormal
hysical findings in those without disease. For the entire
roup of subjects, 74% had 1 or more abnormal physical
ndings in the disease group versus 34% in those without
ignificant CVD.
NP by age groups and cardiovascular diagnosis. Plasma
NP was higher overall in the neonatal group, with or
ithout significant cardiac disease, than in the older age
roup. Figure 1 illustrates the distribution of BNP by age
roups and presence of disease. The median BNP for
eonates with disease was 526 pg/ml (mean 1,017  1,128
g/ml) versus 96 pg/ml (mean 134 130 pg/ml, p 0.001)
or those without disease. The median BNP for the older
ge group with disease was 122 pg/ml (mean 824  1,330
g/ml) versus 22 pg/ml (mean 66  96 pg/ml, p  0.001)
or those without disease. When significant CVD was
urther divided into those with an anatomic defect or
ithout an anatomic defect, BNP remained elevated in both
ge groups compared with their nondisease group (Fig. 2). In the
eonatal group, median BNP was 872 pg/ml (mean 1,350 
Disease Nondisease p Value*
62 (62) 38 (38)
26 (42) 13 (34) 0.999
0.2 (0–225) 1.1 (0–210) 0.099
3.9 (1.8–99) 3.4 (2.3–88) 0.798
31 (74) 11 (26)
11 (35) 5 (45) 1.0
0.9 (0–5) 0.9 (0–5) 0.612
3.3 (2.1–4.8) 3.2 (2.6–3.5) 0.295
31 (53) 27 (47)
15 (48) 8 (30) 0.690
2.6 (0.3–225) 1.9 (0.3–210) 0.591
4.6 (1.8–99) 4.7 (2.3–88) 0.680
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BNP to Diagnose Significant CVD October 6, 2009:1467–75,387 pg/ml) in those with a CVD with anatomic defect
nd 446 pg/ml (mean 613 499 pg/ml) in those with CVD
ithout an anatomic defect. In the older age group, median
NP was 613 pg/ml (mean 887 865 pg/ml) in those with
VD from an anatomic defect and 106 pg/ml (mean 793
,521 pg/ml) in those with CVD without an anatomic
efect. There is statistical significance in the comparison of
he difference in BNP among the 3 groups (Fig. 2). The
ifference is also statistically significant in the independent
omparison between each of the disease groups with the
ondisease group (p  0.05 for each of the age group
omparisons). The specific cardiovascular diagnoses are
hown in Tables 3 and 4. The group without disease
ncompassed a wide range of diagnoses, the most common
f which included chest infection, lung disease, and meta-
hysical Examination Findingsy the Cardiology Consulta tTable 2 Physical Examination Findingsby the Cardiology Consultant
Finding n (%)
Older age group (n  58)
No disease subgroup (n  27)
Abnormal findings absent 18 (67)
Abnormal findings present 9 (33), 1 with multiple abnormalities
Murmur 3
Increased pre-cordial impulse 2
Congestion* 2
Pulmonary† 3
Disease subgroup (n  31)
Abnormal findings absent 9 (29)
Abnormal findings present 22 (71), 12 with multiple abnormalities
S3/S4 8
Loud single S2 7
Murmur 5
Increased pre-cordial impulse 4
Congestion* 7
Pulmonary† 4
Diminished pulses/perfusion 5
Neonatal group (n  42)
No disease subgroup (n  11)
Abnormal findings absent 7 (64)
Abnormal findings present 4 (36), 0 with multiple abnormalities
S3/S4 1
Murmur 1
Pulmonary† 2
Disease subgroup (n  31)
Abnormal findings absent 7 (23)
Abnormal findings present 24 (77), 6 with multiple abnormalities
S3/S4 2
Loud single S2 4
Murmur 13
Increased pre-cordial impulse 10
Congestion* 2
Pulmonary† 2
Diminished pulses/perfusion 1
Signs of congestion, such as edema, hepatomegaly, or jugular venous distension. †Pulmonary
bnormal findings, such as rales, wheezing, and increased work of breathing.olic and neuromuscular diseases.ength of hospital stay and survival. Subjects with CVD
ad a longer length of stay (median 7 days) compared with
hose without disease (median 5 days, p  0.04). The
orrelation of BNP to the length of stay in the entire group
f subjects with significant CVD showed an r coefficient of
.27 with p  0.041. Within the neonatal group, the
orrelation coefficient was 0.56 (p  0.001). Within the
lder age group, the correlation coefficient was 0.16 (p 
.418). In the length-of-stay analysis, the 4 subjects who
ied were excluded. Furthermore, the association of survival
ith BNP was assessed by comparing BNP in the subjects
ith CVD who survived (n  58) with that of those who
ied (n  4) during the same hospital stay. Those who
urvived had a median BNP of 314 pg/ml (mean 868 
,141 pg/ml) versus 776 pg/ml (mean 1,682 2,242 pg/ml)
or those who died (p  0.344). These 2 findings suggest
hat a higher BNP is associated with greater morbidity and
everity of disease, particularly in the neonatal group.
ccuracy of the BNP assay for clinician-judged
VD. Receiver-operating characteristic curves were gener-
ted for each age group. Characteristics of these curves are
epicted by the area under the curve, confidence interval, and
value compared with a diagonal reference line (Table 5).
utoff values that favored sensitivity while maintaining an
dequate combination of sensitivity and specificity are
hown. Optimal BNP cutoff values to diagnose significant
VD were higher for the neonatal group than for the older
Figure 1 Distribution of BNP by the Presence of Cardiovascular
Disease in the Neonatal and Older Age Groups
Blue bars  cardiovascular disease absent; red bars  cardiovascular disease
present. BNP  B-type natriuretic peptide.
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October 6, 2009:1467–75 BNP to Diagnose Significant CVDge group. In the neonatal group, a BNP cutoff of 170
g/ml produced a sensitivity of 94%, specificity of 73%,
ositive predictive value (PPV) of 91%, and negative pre-
ictive value (NPV) of 80%. For the older age group, the
ptimal BNP cutoff of 41 pg/ml delivered a sensitivity of
7%, a specificity of 70%, PPV of 77%, and an NPV of 83%.
hen all the subjects are combined, an intermediate cutoff
f 99 pg/ml provided the best sensitivity and specificity. As
hown in Table 5, the accuracy of the BNP assay is
Figure 2 Distribution of BNP by Category of
Cardiovascular Disease in the 2 Age Groups
Blue bars  cardiovascular disease absent; yellow bars  cardiovascular dis-
ease without anatomic defect; red bars  cardiovascular disease with ana-
tomic defect. BNP  B-type natriuretic peptide.
linical Diagnoses in Each of the Disease Categories in the Older ATable 3 Clinical Diagnoses in Each of the Disease Categories i
No CVD (n  27) CVD With Anatomic D
Chest infection, n  7 Anomalous pulmonary venous retu
Dyspnea, n  12 Ventricular septal defect with PAH
1 with murmur Patent ductus arteriosus, n  1
2 with cyanosis Anomalous left coronary artery fro
4 with respiratory failure Coarctation, n  2
3 with cardiomegaly Pulmonary vein stenosis and PAH,
1 with gastroesophageal reflux Double-outlet right ventricle subao
1 with meningitis Pulmonic valve stenosis, n  1
Connective tissue disorder, n  1
Failure to thrive, n  2
Upper airway obstruction, n  1
Acute abdomen, n  1
Malignancy, n  1
Pericarditis, n  2VD  cardiovascular disease; LVSD  left ventricular systolic dysfunction; PAH  pulmonary arterial hymproved when separate age groups are considered, com-
ared with lumping the entire study population into 1
roup.
If the maximal NPV (the chance of those with a negative
est to not have disease) was used to determine cutoff values,
ifferent cutoffs and their respective accuracy values were
enerated for the neonatal and total group but remained the
ame (41 pg/ml) for the older age group (Table 6). For the
eonatal group, using a higher NPV (88%) resulted in a
igher sensitivity (97%) but a lower specificity (64%) and
PV (88%). In the combined group, using a maximal NPV
f 81%, the sensitivity increased to 92%, with the specificity
ecreasing to 55% and PPV to 77%.
ultivariate analysis. In a logistic regression model, age,
ex, weight, CXR, and length of stay were not found to
nfluence BNP. A linear regression model showed all of
hese variables to characterize BNP. Because neonatal status
as pre-defined at the outset of the study to influence BNP,
he data were stratified by neonatal or older age status. In
he neonatal-stratified model, the length of stay was
redictive of BNP (p  0.05). In the older age stratum,
ge, weight, and CXR were predictive of the BNP level
p  0.05).
iscussion
he Better Not Pout Children! study is the largest prospec-
ive study to assess the accuracy of plasma BNP to diagnose
VD in the pediatric population. It was designed as a field
est to evaluate BNP as a potential diagnostic tool for
ront-line physicians to diagnose significant CVD when
here is a suspicion of such in the acute care setting. These
re clinical conditions that should be recognized and differ-
ntiated accurately from non-CVD processes without delay.
he principal findings of this study are that a neonate up to
days of age with possible cardiac-related findings and a
NP of 170 pg/ml has a 91% chance of having significant
VD; in a child older than this age, a BNP of 41 pg/ml
roupOlder Age Group
(n  10) CVD Without Anatomic Defect (n  21)
2 PAH with lung disease, n  2
Idiopathic PAH, n  1
Myocarditis, n  3
onary artery, n  1 Cardiomyopathy, n  9
Dilated, n  5 (1 nutritional, 2 malignancy)
Infiltrative, n  1
nosis, n  1 Noncompaction, n  1
Restrictive, n  1
Chronic anemia, n  1
Myocardial infarction idiopathic, n  1
LVSD, n  5
From hypertension, n  3
Chemotherapy toxicity (acute), n  2ge Gn the
efect
rn, n 
, n  1
m pulm
n  1
rtic stepertension.
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BNP to Diagnose Significant CVD October 6, 2009:1467–75redicts a 77% chance that significant CVD is present.
avoring a high sensitivity is important in identifying heart
isease in the acute care setting in children, especially
nfants, because a delayed diagnosis can affect treatment
esponse and outcome.
Using cutoff values based on the maximal NPV to
mprove the ability to rule out significant CVD in the
resence of a negative test also delivered good sensitivities
or both groups. However, the specificity and PPV do
ecline, and the maximal NPVs generated are not suffi-
iently high enough that they would be recommended over
he ones generated from favoring a more balanced accuracy
rofile that still favors sensitivity. One possible explanation
or why the maximal NPVs did not approach 95% is the
igh prevalence of disease in the study population. Enrolled
ubjects presented with signs and symptoms that made the
ront-line physician suspicious of significant CVD. It is also
ossible that the acuity and severity of the disease process in
he non-CVD group could have raised the basal level of
NP production.
In summary, at an acceptable level of sensitivity and
PV, the specificity and PPV were not compromised.
hese results demonstrated that plasma BNP, when used
ith a clinical suspicion of significant CVD by the front-
ine physician, can be an accurate biomarker in the pediatric
opulation.
linical Diagnoses in Each of the Disease Categories in the NeonaTable 4 Clinical Diagnoses in Each of the Disease Categories i
No CVD (n  11) CVD With Anatomi
Chest infection, n  3 Ventricular septal defect, n
Lung disease, n  2 Patent ductus arteriosus, n
Tachypnea and murmur, n  2 Coarctation, n  1
Transient tachypnea of newborn, n  2 Transposition of the great a
Myopathy and dyspnea, n  1 2 with coarctation and P
Asphyxia and murmur, n  1 1 with LVSD and RVSD
Aortic stenosis and PAH, n
Shone’s complex and coarc
Atrioventricular septal defe
Pulmonic valve stenosis, n
Aneurysm of ductus arterio
stenosis and LVSD PAH
Tetralogy of Fallot, n  1
Ebstein’s with PAH, n  1
Hypoplastic left heart syndr
VSD  right ventricular systolic dysfunction; other abbreviations as in Table 3.
ccuracy of Diagnosing Cardiovascular Disease by the BNP Assayn the Basis of Higher Sensitivity and Best Ov rall Accuracy ValueTable 5 Accuracy of Diagnosing Card ov cular Disease by thon the Basis of Higher Sensitivity and Best Overall Acc
Group n AUC  SE p Value (95% CI)
Neonatal 42 0.90 0.05 0.001 (0.79–1.00)
Older age 58 0.81 0.06 0.001 (0.69–0.92)
Combined group 100 0.84 0.04 0.001 (0.77–0.92)haracteristics of the receiver-operating characteristic curves are depicted by the AUC, SE, and comparis
AUC  area under the curve; BNP  B-type natriuretic peptide; CI  confidence interval; NPV  negattudy design. Prospective studies that attempt to measure
he accuracy of BNP in children are scarce, are limited by
mall sample size, and use different enrollment and diag-
ostic criteria (18–20). In the Better Not Pout Children!
tudy, enrollment of subjects without known pre-existing
VD was critical because it eliminates selection bias. We
nrolled subjects from acute care settings because these are
he places where the initial presentation of significant CVD
s most likely to occur. Furthermore, blinding caregivers to
he BNP results and using the cardiologist’s consult as the
old standard for diagnosis resembles how the BNP assay
ould be applied in clinical practice and also parallels the
ethods used in previous landmark adult studies (6–9).
eparation of the subjects by age groups based on previously
nown physiologic data allows for a more precise
omparison.
One of the most important aspects of the current study is
he selection of the nondisease group. A recently published
ediatric prospective study by Maher et al. (20) also at-
empted to measure the accuracy of the assay. In that study,
he nondisease population was sampled from the emergency
epartment, whereas the disease population required an
ntensive care admission, allowing for the possibility of an
scertainment bias in that the control subjects were less ill
han the disease population. Perhaps not surprisingly, a
emarkably high sensitivity and specificity of 97% were
oupNeonatal Group
ct (n  16) CVD Without Anatomic Defect (n  15)
Arteriovenous malformation, n  2
1 with PAH and LVSD
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4 idiopathic
3 with chest infection
PAH, n  1 1 with mediastinal mass
PAH, n  1 Dilated cardiomyopathy and PAH, n  1
th pulmonary artery
1
VSD, n  1
Assay
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October 6, 2009:1467–75 BNP to Diagnose Significant CVDbtained. In the Better Not Pout Children! study, the
ondisease and disease subjects required a similar clinical
resentation and were sampled concurrently from the same
ource, thereby ensuring that both populations possessed a
imilar disease acuity and severity. Although the current
tudy finds a lower sensitivity and specificity compared with
hat of Maher et al. (20), it probably provides a more valid
easurement of the accuracy of the BNP assay in the
ediatric population.
It should also be emphasized that in the Better Not Pout
hildren! study, BNP was not used as a screening test of all
cute care patients. The enrolled subjects presented with
igns and symptoms suggestive of significant CVD as
iscerned by the front-line physician using all available data
eemed necessary without a cardiology consult. Therefore,
he population studied is enriched with disease subjects,
hich can increase the sensitivity and PPV while possibly
isfavoring the specificity and NPV. On the basis of this
tudy design and entry criteria, we view the application of
he BNP test as a way to strengthen and not replace clinical
cumen.
NP results by age groups. It should be underscored that
ifferent cutoff values for different age groups is important in
he pediatric population. The decline in the accuracy of the
ssay is particularly large in the neonatal population if these
ubjects were to be grouped with older children. This was
ot unexpected because the combined group’s cutoff (99
g/ml) is significantly lower than the optimal cutoff (170
g/ml) generated for the neonates. In other words, in using
combined age group cutoff, even though neonates with
isease will still be identified, the false-positive rate and
herefore specificity will suffer significantly. Similarly, the
ensitivity will also be lessened in the older age group if a
igher cutoff value is used.
The higher cutoff value in neonates is not surprising, as
tudies have shown higher natriuretic peptide levels in
ealthy neonates compared with those of other age groups.
atriuretic peptide levels decrease after birth, reaching a
teady level by 4 to 7 days of age (12–14). The natriuretic
eptides may play an important role in the homeostasis of
he fetal-neonatal-mature transitional circulation. Total
ody water is increased in the newborn, and the acute and
ramatic increases in the systemic pre-load and afterload to
he pulmonary arterial circulation in conjunction with a stiff
eonatal myocardium (21,22) could lead to a physiologic
elease of natriuretic peptides. Because the newborn may be
Accuracy of Diagnosing Cardiovascular Diseaseby the BNP Assay on the Basis of the MaximalTable 6 ccuracy of Di gnosing Card ov cby the BNP Assay on the Basis of t
Group Cutoff Sensitivity, %
Neonatal 122 97
Older age 41 87
Combined group 44 92
Abbreviations as in Table 5.ess responsive to natriuretic peptides (23), a higher secreted oevel is required to promote the well-recognized natriuresis
hat commences in the first week of life. During this time,
he precipitous decrease in pulmonary vascular resistance
ay also be promoted by natriuretic peptides (24–26).
ltogether, the elevated BNP values followed by their
ecrease after the first week of life may be an adaptive
esponse to these cardiophysiologic requirements. This age
ariation was 1 reason we chose to separate the age groups
t 7 days of age. Although the levels continue to decline
fter the first week of life in healthy individuals, the change
s small after this time until adulthood, when the values
ncrease gradually again. However, from the multivariate
nalysis, it does appear that there remains an age factor in
he older age group. This is not altogether surprising,
ecause the physiologic decline is a continuum (albeit very
mall), and in CVD, the decline may be delayed. This could
ffect the accuracy of the BNP assay at the lower age range
f the non-neonates. The design of future studies to improve
pon the current study’s assessment of BNP to diagnose
ignificant CVD should take this into consideration.
NP and type of CVD. When BNP was examined by
isease category, the disease patients either with or without
n anatomic defect were shown to have significantly higher
alues than those without disease. This suggests that BNP
an be used to diagnose significant CVD regardless of
tiology. Neither our study nor any others to date have been
dequately powered to use BNP to differentiate between
natomic versus functional heart disease when contributing
actors are properly controlled. Moreover, the current study
id not attempt to stratify the severity of the cardiovascular
ondition to the magnitude of BNP elevation. These are
mportant areas of investigation in the future.
To further improve the utility of BNP as a diagnostic
iomarker for the pediatric population, future studies should
ssess the accuracy of BNP when it is added to the physical
xamination and CXR as interpreted by the front-line
hysician. For the cardiologist who is consulting with a
istant primary caregiver, the BNP level may also aid in
etermining whether an immediate echocardiogram or re-
erral is necessary. Given our findings that suggest a higher
NP level is associated with length of stay and possibly
urvival, it is important to test whether BNP has a role in
rognostication (27). Lastly, future studies can culminate in
linical trials to assess whether adding BNP to other routine
onitoring tests can positively impact treatment response or
isease
aximal NPV
Specificity, % PPV, % NPV, %
64 88 88
70 77 83
55 77 81NPVular D
he Mutcome.
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BNP to Diagnose Significant CVD October 6, 2009:1467–75tudy limitations. Although large compared with that of
xisting studies, the sample size in this study remains a
imitation. Pediatric CVDs and their presentations are
eterogeneous, resulting in a wide range of ventricular
ysfunction and heart failure severity, the latter being
articularly difficult to grade appropriately. The necessity of
umping subjects of different ages into only 2 groups can also
ffect the accuracy. Furthermore, a clear-cut definition of
ignificant CVD and the means to accurately diagnose it
00% correctly (the gold standard) does not exist in pedi-
tric cardiology. Hence, the consulting cardiologist’s official
iagnosis was used in this study, even though this would not
uarantee standardization and complete objectivity. The
linician must cautiously interpret a simple cutoff in a
uantitative test that is not 100% accurate, such as we
ropose in this study. Not only was the patient population
eterogeneous in terms of the demographics (age, sex, and
eight), but noncardiovascular processes could also poten-
ially affect the individual patient’s BNP result. Therefore,
he BNP result must be interpreted under the clinical
ontext for which it was ordered. Nevertheless, the pediatric
utoffs generated by this study do provide a much-needed
oint of reference for the clinician to determine whether a
ardiology consult is necessary, especially when these cutoffs
re different from those of the adult population.
onclusions
he Better Not Pout Children! study validates the utility of
single plasma BNP measurement to diagnose a variety of
ignificant CVD in the pediatric acute care setting. In this
eterogeneous population, it is important to identify cutoff
alues applicable to neonates and older children. The cutoffs
ffering optimal accuracy are 170 pg/ml for neonates to 7
ays of age and 41 pg/ml for those who are older than 7 days
o the age of 19 years. The cutoffs are different between
hese 2 age groups. Equally important, the study results are
lso different from published and company-recommended
utoffs of 80 to 100 pg/ml for adults (6–9). Because
ongenital heart disease can present early in the neonatal
eriod (e.g., ductal-dependent lesions), and children are less
orthcoming with their complaints than adults, the timely
ecognition of significant CVD is important, and the
easurement of BNP can be useful in the diagnostic
rocess.
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